Active substances
Dapagliflozin + Metformin
- SFDA 10
- US FDA 11
- Health Canada 6
- US price lines 4
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Dezeroga-Met | 5,1000 mg,mg | Prolonged-release film-coated tablet · Oral use | 56 Blister | SAR 110.90 | Generic · Prescription | Med City Pharma | Valid |
| Dezeroga-Met | 10,1000 mg,mg | Prolonged-release film-coated tablet · Oral use | 28 Blister | SAR 107.80 | Generic · Prescription | Med City Pharma | Valid |
| Divinusmet | 1000,5 mg,mg | Film-coated tablet · Oral use | 60 Bottle | SAR 119.40 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Divinusmet | 1000,10 mg,mg | Film-coated tablet · Oral use | 30 Bottle | SAR 116.10 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Volzamet XR | 5/1000 mg | Film-coated tablet · Oral use | 60 Blister | SAR 109.70 | Generic · Prescription | Cooper Pharma Arabia | Valid |
| Volzamet XR | 10/1000 mg | Film-coated tablet · Oral use | 30 Blister | SAR 106.60 | Generic · Prescription | Cooper Pharma Arabia | Valid |
| XIGDUO XR 10 mg/1000 mg Film Coted Tablet | 1000,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 124.40 | NCE · Prescription | AstraZeneca AB | Valid |
| XIGDUO XR 10 mg/500 mg Film Coted Tablet | 500,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 122.45 | NCE · Prescription | AstraZeneca AB | Valid |
| XIGDUO XR 5 mg/1000 mg Film Coted Tablet | 1000,5 mg,mg | Film-coated tablet · Oral use | 56 Blister | SAR 128.00 | NCE · Prescription | AstraZeneca AB | Valid |
| XIGDUO XR 5 mg/500 mg Film Coted Tablet | 500,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 108.40 | NCE · Prescription | AstraZeneca AB | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| XIGDUO XR | 5MG;500MG; 5MG;1GM; 10MG;500MG; 10MG;1GM; 2.5MG;1GM | tablet, extended release · oral | ASTRAZENECA AB | Prescription | 29 Oct 2014 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG; 5MG;1GM; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | MICRO LABS | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG; 5MG;1GM; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | MSN | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG; 5MG;1GM; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | AUROBINDO PHARMA | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | SUN PHARM | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | CIPLA LTD | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG; 5MG;1GM; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | MACLEODS PHARMS | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG; 5MG;1GM; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | ALKEM LABS LTD | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG; 5MG;1GM; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | LUPIN | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 2.5MG;1GM; 5MG;500MG; 5MG;1GM; 10MG;500MG; 10MG;1GM | tablet, extended release · oral | TEVA PHARMS USA INC | Prescription | 6 Apr 2026 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | tablet, extended release · oral | CIPLA | Prescription | 6 Apr 2026 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-DAPAGLIFLOZIN-METFORMIN | 02536153 | 850 MG; 5 MG | TABLET · ORAL | APOTEX INC |
| APO-DAPAGLIFLOZIN-METFORMIN | 02536161 | 1000 MG; 5 MG | TABLET · ORAL | APOTEX INC |
| AURO-DAPAGLIFLOZIN / METFORMIN | 02533073 | 5 MG; 850 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-DAPAGLIFLOZIN / METFORMIN | 02533081 | 5 MG; 1000 MG | TABLET · ORAL | AURO PHARMA INC |
| XIGDUO | 02449935 | 5 MG; 850 MG | TABLET · ORAL | ASTRAZENECA CANADA INC |
| XIGDUO | 02449943 | 5 MG; 1000 MG | TABLET · ORAL | ASTRAZENECA CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DAPAGLIFLOZIN-METFORMIN ER 10-1,000 MG TABLET | $0.71952 | per EA | 23 Sep 2026 |
| US NADAC | DAPAGLIFLOZIN-METFORMIN ER 10-500 MG TABLET | $0.80198 | per EA | 23 Sep 2026 |
| US NADAC | DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET | $0.46063 | per EA | 23 Sep 2026 |
| US NADAC | DAPAGLIFLOZIN-METFORMIN ER 5-500 MG TABLET | $0.70725 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Dapagliflozin 5mg / Metformin 1g tablets | £36.59 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Dapagliflozin 5mg / Metformin 850mg tablets | £36.59 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.